Related Experiment Video
Updated: Jun 17, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Case Report: Clinical manifestations reported in a canine after ingesting ruxolitinib phosphate (Opzelura®)
Leah D Swanson1,2, Renee D Schmid1,2, Steven Butt3
1SafetyCall International, Bloomington, MN, United States.
Abstract:
This case report describes a canine patient that developed cardiovascular and ocular abnormalities following ingestion of ruxolitinib phosphate 1.5% topical cream. The objective of this report is to characterize the exposure history, clinical presentation, diagnostic findings, therapeutic interventions, and to evaluate ruxolitinib phosphate within the context of its pharmacologic class, emphasizing similarities with related veterinary medications. Building on a recently published retrospective study of oclacitinib maleate overdoses, this case highlights shared clinical manifestations of ruxolitinib phosphate overdose and contributes to a broader understanding of JAK inhibitor toxicosis in veterinary medicine.
More Related Videos
Related Concept Videos
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Acute Pancreatitis II: Clinical Manifestations and Management
Toxoplasmosis
Peptic Ulcer Disease III: Clinical Manifestations and Complications
Intestinal Obstruction II: Pathophysiology

